Literature DB >> 23493088

Tumor necrosis factor receptor-associated factor 2 signaling provokes adverse cardiac remodeling in the adult mammalian heart.

Vijay G Divakaran1, Sarah Evans, Veli K Topkara, Abhinav Diwan, Jana Burchfield, Feng Gao, Jianwen Dong, Huei-Ping Tzeng, Natarajan Sivasubramanian, Philip M Barger, Douglas L Mann.   

Abstract

BACKGROUND: Tumor necrosis factor superfamily ligands provoke a dilated cardiac phenotype signal through a common scaffolding protein termed tumor necrosis factor receptor-associated factor 2 (TRAF2); however, virtually nothing is known about TRAF2 signaling in the adult mammalian heart. METHODS AND
RESULTS: We generated multiple founder lines of mice with cardiac-restricted overexpression of TRAF2 and characterized the phenotype of mice with higher expression levels of TRAF2 (myosin heavy chain [MHC]-TRAF2(HC)). MHC-TRAF2(HC) transgenic mice developed a time-dependent increase in cardiac hypertrophy, left ventricular dilation, and adverse left ventricular remodeling, and a significant decrease in LV+dP/dt and LV-dP/dt when compared with littermate controls (P<0.05 compared with littermate). During the early phases of left ventricular remodeling, there was a significant increase in total matrix metalloproteinase activity that corresponded with a decrease in total myocardial fibrillar collagen content. As the MHC-TRAF2(HC) mice aged, there was a significant decrease in total matrix metalloproteinase activity accompanied by an increase in total fibrillar collagen content and an increase in myocardial tissue inhibitor of metalloproteinase-1 levels. There was a significant increase in nuclear factor-κB activation at 4 to 12 weeks and jun N-terminal kinases activation at 4 weeks in the MHC-TRAF2(HC) mice. Transciptional profiling revealed that >95% of the hypertrophic/dilated cardiomyopathy-related genes that were significantly upregulated genes in the MHC-TRAF2(HC) hearts contained κB elements in their promoters.
CONCLUSIONS: These results show for the first time that targeted overexpression of TRAF2 is sufficient to mediate adverse cardiac remodeling in the heart.

Entities:  

Keywords:  TNF receptor–associated factor 2; dilated cardiomyopathy; inflammation; tumor necrosis factor superfamily

Mesh:

Substances:

Year:  2013        PMID: 23493088      PMCID: PMC3672470          DOI: 10.1161/CIRCHEARTFAILURE.112.000080

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  28 in total

1.  Cellular remodeling in heart failure disrupts K(ATP) channel-dependent stress tolerance.

Authors:  Denice M Hodgson; Leonid V Zingman; Garvan C Kane; Carmen Perez-Terzic; Martin Bienengraeber; Cevher Ozcan; Richard J Gumina; Darko Pucar; Fergus O'Coclain; Douglas L Mann; Alexey E Alekseev; Andre Terzic
Journal:  EMBO J       Date:  2003-04-15       Impact factor: 11.598

2.  Neuroendocrine response in acute heart failure and the influence of treatment.

Authors:  M Broqvist; U Dahlström; B E Karlberg; E Karlsson; T Marklund
Journal:  Eur Heart J       Date:  1989-12       Impact factor: 29.983

3.  Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha.

Authors:  D Bryant; L Becker; J Richardson; J Shelton; F Franco; R Peshock; M Thompson; B Giroir
Journal:  Circulation       Date:  1998-04-14       Impact factor: 29.690

4.  Role of the NF-kappaB signaling cascade and NF-kappaB-targeted genes in failing human hearts.

Authors:  Sudhiranjan Gupta; Subha Sen
Journal:  J Mol Med (Berl)       Date:  2005-08-17       Impact factor: 4.599

5.  Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure.

Authors:  Thor Ueland; Arne Yndestad; Erik Øie; Geir Florholmen; Bente Halvorsen; Stig S Frøland; Svein Simonsen; Geir Christensen; Lars Gullestad; Pål Aukrust
Journal:  Circulation       Date:  2005-05-09       Impact factor: 29.690

6.  Evans Blue Dye as an in vivo marker of myofibre damage: optimising parameters for detecting initial myofibre membrane permeability.

Authors:  P W Hamer; J M McGeachie; M J Davies; M D Grounds
Journal:  J Anat       Date:  2002-01       Impact factor: 2.610

7.  Transforming growth factor-beta receptor antagonism attenuates myocardial fibrosis in mice with cardiac-restricted overexpression of tumor necrosis factor.

Authors:  Yasushi Sakata; Amanda L Chancey; Vijay G Divakaran; Kenichi Sekiguchi; Natarajan Sivasubramanian; Douglas L Mann
Journal:  Basic Res Cardiol       Date:  2007-11-21       Impact factor: 17.165

8.  TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways.

Authors:  Sandra B Haudek; George E Taffet; Michael D Schneider; Douglas L Mann
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

9.  Targeted overexpression of noncleavable and secreted forms of tumor necrosis factor provokes disparate cardiac phenotypes.

Authors:  Abhinav Diwan; Ziad Dibbs; Shintaro Nemoto; Gilberto DeFreitas; Blase A Carabello; Natarajan Sivasubramanian; Eric M Wilson; Francis G Spinale; Douglas L Mann
Journal:  Circulation       Date:  2003-12-29       Impact factor: 29.690

10.  Desmin mediates TNF-alpha-induced aggregate formation and intercalated disk reorganization in heart failure.

Authors:  Panagiota Panagopoulou; Constantinos H Davos; Derek J Milner; Emily Varela; Joann Cameron; Douglas L Mann; Yassemi Capetanaki
Journal:  J Cell Biol       Date:  2008-06-02       Impact factor: 10.539

View more
  20 in total

1.  Catechin ameliorates cardiac dysfunction in rats with chronic heart failure by regulating the balance between Th17 and Treg cells.

Authors:  Qi Zhang; Li-Qun Hu; Chang-Sen Yin; Ping Chen; Hong-Qi Li; Xin Sun; Guang Yan
Journal:  Inflamm Res       Date:  2014-04-24       Impact factor: 4.575

2.  Tumor necrosis factor receptor-associated factor 2 mediates mitochondrial autophagy.

Authors:  Kai-Chun Yang; Xiucui Ma; Haiyan Liu; John Murphy; Philip M Barger; Douglas L Mann; Abhinav Diwan
Journal:  Circ Heart Fail       Date:  2014-10-22       Impact factor: 8.790

3.  Impaired Protein Quality Control During Left Ventricular Remodeling in Mice With Cardiac Restricted Overexpression of Tumor Necrosis Factor.

Authors:  Justin Hartupee; Gabor D Szalai; Wei Wang; Xiucui Ma; Abhinav Diwan; Douglas L Mann
Journal:  Circ Heart Fail       Date:  2017-12       Impact factor: 8.790

4.  G3BP2 is involved in isoproterenol-induced cardiac hypertrophy through activating the NF-κB signaling pathway.

Authors:  Hui-Qi Hong; Jing Lu; Xiu-Li Fang; Yu-Hong Zhang; Yi Cai; Jing Yuan; Pei-Qing Liu; Jian-Tao Ye
Journal:  Acta Pharmacol Sin       Date:  2017-08-17       Impact factor: 6.150

5.  Functional significance of the discordance between transcriptional profile and left ventricular structure/function during reverse remodeling.

Authors:  Veli K Topkara; Kari T Chambers; Kai-Chien Yang; Huei-Ping Tzeng; Sarah Evans; Carla Weinheimer; Attila Kovacs; Jeffrey Robbins; Philip Barger; Douglas L Mann
Journal:  JCI Insight       Date:  2016-04-06

6.  Response by Liu to Letter Regarding Article, "Cardioprotective Role of Tumor Necrosis Factor Receptor-Associated Factor 2 by Suppressing Apoptosis and Necroptosis".

Authors:  Qinghang Liu
Journal:  Circulation       Date:  2018-04-17       Impact factor: 29.690

7.  Cardioprotective Role of Tumor Necrosis Factor Receptor-Associated Factor 2 by Suppressing Apoptosis and Necroptosis.

Authors:  Xiaoyun Guo; Haifeng Yin; Lei Li; Yi Chen; Jing Li; Jessica Doan; Rachel Steinmetz; Qinghang Liu
Journal:  Circulation       Date:  2017-06-01       Impact factor: 29.690

Review 8.  Recent advances of adapter proteins in the regulation of heart diseases.

Authors:  Li Tao; Linna Jia; Yuntian Li; Chengyun Song; Zheng Chen
Journal:  Heart Fail Rev       Date:  2017-01       Impact factor: 4.214

Review 9.  Tumor Necrosis Factor-α in Heart Failure: an Updated Review.

Authors:  Sarah M Schumacher; Sathyamangla V Naga Prasad
Journal:  Curr Cardiol Rep       Date:  2018-09-26       Impact factor: 2.931

10.  TNF receptor-activated factor 2 mediates cardiac protection through noncanonical NF-κB signaling.

Authors:  Sarah Evans; Huei-Ping Tzeng; Deborah J Veis; Scot Matkovich; Carla Weinheimer; Attila Kovacs; Philip M Barger; Douglas L Mann
Journal:  JCI Insight       Date:  2018-02-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.